Literature DB >> 26867706

Survival in Children With Down Syndrome Undergoing Single-Ventricle Palliation.

John L Colquitt1, Shaine A Morris1, Susan W Denfield1, Charles D Fraser2, Yunfei Wang1, W Buck Kyle3.   

Abstract

BACKGROUND: We describe survival in patients with Down syndrome (DS) with single-ventricle anatomy and palliation and characterize risk factors associated with mortality.
METHODS: All patients with DS and single-ventricle anatomy documented in the electronic medical record at our institution from January 1, 1992, to May 1, 2014, were compared with patients with unbalanced atrioventricular septal defects and single-ventricle anatomy, without DS or heterotaxy, during the same period. Survival analysis was performed to evaluate factors associated with mortality, including the presence of DS.
RESULTS: There were 28 patients with DS and 30 patients without DS. One-year survival with DS was 75% (95% CI: 55% to 87%); 5-year survival was 61% (95% CI: 40% to 76%). All DS deaths except one occurred before 2 years of age. One-year non-DS survival was 93% (95% CI: 76% to 98%); 5-year survival was 85% (95% CI: 64% to 94%). Factors associated with death by univariable analysis included DS (p = 0.04), pulmonary vascular resistance (PVR) of at least 3 Wood units × meter(2) (WUm(2)) in the first year of life (p = 0.03), and moderate-to-severe atrioventricular valve regurgitation (p = 0.1). In combined analysis, when accounting for PVR of at least 3 WUm(2) (hazard ratio [HR] 9.8, 95% CI: 1.1 to 83.5, p = 0.04), DS was not associated with increased mortality (HR 1.5, 95% CI: 0.3 to 7.8, p = 0.66). No patient with DS with PVR less than 3 WUm(2) died.
CONCLUSIONS: Children with DS and single-ventricle anatomy have excellent survival when PVR is less than 3 WUm(2) in the first year of life, with minimal mortality beyond 2 years of age. When accounting for PVR, DS alone is not associated with increased mortality in patients with single-ventricle anatomy.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26867706     DOI: 10.1016/j.athoracsur.2015.11.047

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  7 in total

1.  Copy Number Variants of Undetermined Significance Are Not Associated with Worse Clinical Outcomes in Hypoplastic Left Heart Syndrome.

Authors:  Andrew L Dailey-Schwartz; Hanna J Tadros; Mahshid Sababi Azamian; Seema R Lalani; Shaine A Morris; Hugh D Allen; Jeffrey J Kim; Andrew P Landstrom
Journal:  J Pediatr       Date:  2018-08-29       Impact factor: 4.406

2.  Postoperative and long-term outcomes in children with Trisomy 21 and single ventricle palliation.

Authors:  Jennifer K Peterson; Shaun P Setty; Jessica H Knight; Amanda S Thomas; James H Moller; Lazaros K Kochilas
Journal:  Congenit Heart Dis       Date:  2019-07-22       Impact factor: 2.007

3.  Trisomy 21 Patients Undergoing Cavopulmonary Connections Need Improved Preoperative and Postoperative Care.

Authors:  Philip Allen; Brett R Anderson; Emile Bacha; Damien J LaPar
Journal:  Ann Thorac Surg       Date:  2020-11-06       Impact factor: 5.102

Review 4.  Advances in the Understanding of the Genetic Determinants of Congenital Heart Disease and Their Impact on Clinical Outcomes.

Authors:  Mark W Russell; Wendy K Chung; Jonathan R Kaltman; Thomas A Miller
Journal:  J Am Heart Assoc       Date:  2018-03-09       Impact factor: 5.501

Review 5.  Surgical palliation of univentricular heart disease in children with Down's syndrome: A systematic review.

Authors:  Saad Q Khoshhal
Journal:  J Taibah Univ Med Sci       Date:  2018-12-01

Review 6.  Pulmonary Hypertension in the Population with Down Syndrome.

Authors:  Douglas S Bush; D Dunbar Ivy
Journal:  Cardiol Ther       Date:  2022-01-16

Review 7.  Perioperative care of adults with Down syndrome: a narrative review.

Authors:  Elizabeth B Malinzak
Journal:  Can J Anaesth       Date:  2021-06-24       Impact factor: 6.713

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.